MolPharm xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Molecular Pharmacology Fast Forward
First published on August 12, 2005; DOI: 10.1124/mol.105.015586


0026-895X/05/6805-1415-1422$20.00
Mol Pharmacol 68:1415-1422, 2005

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
mol.105.015586v1
68/5/1415    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bouchon, B.
Right arrow Articles by Degoul, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bouchon, B.
Right arrow Articles by Degoul, F.

Alkylation of {beta}-Tubulin on Glu 198 by a Microtubule Disrupter

Bernadette Bouchon, Christophe Chambon, Emmanuelle Mounetou, Janine Papon, Elisabeth Miot-Noirault, René C. Gaudreault, Jean-Claude Madelmont, and Françoise Degoul

Unité Mixte de Recherche 484, Institut National de la Santé et de la Recherche Médicale-Université d'Auvergne, Clermont-Ferrand, France (B.B., E.M., J.P., E.M.-N., J.-C.M., F.D.); Plate-forme Protéomique, Institut National de la Recherche Agronomique de Theix, St-Genès-Champanelle, France (C.C.); and Centre de Recherche, Centre Hospitalier Universitaire de Québec, Hôpital St-François d'Assise, Québec City, Québec, Canada (R.C.G.)

We have shown that {beta}-tubulin was alkylated by a microtubule disrupter, N-4-iodophenyl-N'-(2-chloroethyl)urea (ICEU), on a glutamic acid residue at position 198 and not on the previously proposed reactive cysteine 239. ICEU belongs to the 4-substituted-phenyl-N'-(2-chloroethyl) urea class that alkylates mainly cellular proteins. Previous studies have shown that the tert-butyl (tBCEU) and iodo (ICEU) derivatives induce microtubule disruption because of {beta}-tubulin alkylation. tBCEU was supposed to bind covalently to cysteine 239 of {beta}-tubulin, but this binding site was not clearly confirmed (Cancer Res 60:985-992, 2000). We have isolated and analyzed {beta}-tubulin after two-dimensional gel electrophoresis of proteins from B16 cells incubated with ICEU. Alkylated {beta}-tubulin had a lower apparent molecular weight and a more basic isoelectric point than the unmodified protein. Labeled N-4-[125I]CEU was effectively bound to the modified {beta}-tubulin but using matrix-assisted laser desorption ionization/time-of-flight mass spectrometry, we demonstrated that none of the cysteine residues of {beta}-tubulin was linked to the alkylating agent. In contrast, peptide masses at m/z 4883 and 1792 in trypsin or Asp-N digestions of {beta}-tubulin confirmed binding of iodophenylethylureido moiety to peptides [175-213] or [197-208] respectively. Fragmentation analyses by electrospray mass spectrometry using triply charged ions of peptide [175-213] identified a glutamic acid at position 198 as target for alkylation via an ester bond with ICEU. This amino acid located in the intermediate domain of the {beta}-tubulin should play an essential role in the conformational structure necessary for the interaction between dimers in the protofilament.


Received June 6, 2005; accepted August 12, 2005

Address correspondence to: Françoise Degoul, UMR484, INSERM-Université d'Auvergne, BP184, Rue Montalembert, F-63005 Clermont-Fd, France. E-mail: degoul{at}inserm484.u-clermont1.fr




This article has been cited by other articles:


Home page
Molecular Cancer TherapeuticsHome page
L. Cicchillitti, R. Penci, M. Di Michele, F. Filippetti, D. Rotilio, M. B. Donati, G. Scambia, and C. Ferlini
Proteomic characterization of cytoskeletal and mitochondrial class III {beta}-tubulin
Mol. Cancer Ther., July 1, 2008; 7(7): 2070 - 2079.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2005 by the American Society for Pharmacology and Experimental Therapeutics